Literature DB >> 19430877

Pharmacologic treatment to prevent fractures: from markers to patients.

Steven R Cummings1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19430877     DOI： 10.1007/s00198-009-0914-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  9 in total

1.  How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?

Authors:  P D Delmas
Journal:  Bone       Date:  2000-07       Impact factor: 4.398

2.  Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.

Authors:  N H Bjarnason; S Sarkar; T Duong; B Mitlak; P D Delmas; C Christiansen
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

3.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Authors:  P D Delmas; N H Bjarnason; B H Mitlak; A C Ravoux; A S Shah; W J Huster; M Draper; C Christiansen
Journal:  N Engl J Med       Date:  1997-12-04       Impact factor: 91.245

4.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

Authors:  Steven R Cummings; David B Karpf; Fran Harris; Harry K Genant; Kristine Ensrud; Andrea Z LaCroix; Dennis M Black
Journal:  Am J Med       Date:  2002-03       Impact factor: 4.965

5.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

6.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

Authors:  Pierre D Delmas; Kristine E Ensrud; Jonathan D Adachi; Kristine D Harper; Somnath Sarkar; Carlo Gennari; Jean-Yves Reginster; Huibert A P Pols; Robert R Recker; Steven T Harris; Wentao Wu; Harry K Genant; Dennis M Black; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

7.  Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy.

Authors:  Pierre D Delmas; Ego Seeman
Journal:  Bone       Date:  2004-04       Impact factor: 4.398

Review 8.  Treatment of postmenopausal osteoporosis.

Authors:  Pierre D Delmas
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

9.  Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.

Authors:  Douglas C Bauer; Dennis M Black; Patrick Garnero; Marc Hochberg; Susan Ott; John Orloff; Desmond E Thompson; Susan K Ewing; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-05-24       Impact factor: 6.741
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.